載入...
Systemic treatment for metastatic prostate cancer
The management of metastatic prostate cancer (mPCa) has changed over the past ten years. Several new drugs have been approved with significant overall survival benefits in metastatic castration resistant prostate cancer (PCa) including chemotherapy (docetaxel, cabazitaxel), new hormonal therapies (a...
Na minha lista:
| 發表在: | Asian J Urol |
|---|---|
| 主要作者: | |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Second Military Medical University
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6488732/ https://ncbi.nlm.nih.gov/pubmed/31061802 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajur.2019.02.002 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|